|From: NetworkNewsWire (Rep: 0)||Date: 07/06/2018 17:17|
|Forum: Penny Stocks - Msg #1832 - List LXRP msgs ||Thread #674019723 (Rec: 0) |
|NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Out-licenses Disruptive Delivery Technology to Strategically Build Cash Flow|
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has been strategically out-licensing its disruptive delivery technology and focusing on R&D to improve its value and increase cash flow. An article further discussing the company reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://nnw.fm/N6LOm). … Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its outstanding share count at relatively low levels. He said that LXRP is building its cash flow through licensing and R&D, as its technology can be used in other sectors besides cannabis. The company is focused on cannabinoid delivery R&D with its DehydraTECH™ technology, which enhances the performance of beneficial compounds in ingestible products, but it can be used across multiple categories, such as nicotine absorption. The result of all this, according to Bunka, is investors that are respected and a valuation of the company that has grown ‘by close to 2,000 percent’ in recent years.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.